Cue Biopharma (FRA:1UC0) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


FRA:1UC0 Cue Biopharma Inc FRA:1UC0
57 GF Score
Price €25.92
GF Value €51.06
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Cue Biopharma Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Cue Biopharma's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:1UC0 vs TELO, ACET, AARD: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Cue Biopharma's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cue Biopharma Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cue Biopharma's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Cue Biopharma's Margin of Safety % (DCF Earnings Based) falls into.


FRA:1UC0
57GF Score
Cue Biopharma Inc FRA:1UC0
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cue Biopharma (FRA:1UC0) Overvalued in 2026?

Based on GuruFocus' analysis, Cue Biopharma stock appears to be undervalued. The current stock price of €25.92 is trading 49.2% below its estimated GF Value™ of €51.06. GuruFocus considers Cue Biopharma to be Possible Value Trap.

Key valuation signals for FRA:1UC0:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €51.06 vs. price of €25.92 (49.2% below fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the FRA:1UC0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cue Biopharma Business Description

Other Exchanges CUE:USA
Address 40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
57GF Score

Get the complete analysis for FRA:1UC0

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€25.92
Price
€51.06
GF Value